ReviewRevista medica del Instituto Mexicano del Seguro Social2026
[Merkel cell carcinoma: current surgical approaches and multidisciplinary treatment].
Review in Revista medica del Instituto Mexicano del Seguro Social, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous neuroendocrine tumor with poor prognosis, requiring precise surgical management within a multidisciplinary approach. We conducted a narrative review with a structured literature search in biomedical databases (PubMed, Embase, Scopus, Web of Science) and official guidelines (NCCN, ESMO). Thirty high-quality and clinically relevant articles were selected based on methodological rigor and applicability. Wide local excision with 1-2 cm margins remains the standard of care for localized disease. Sentinel lymph node biopsy should be performed in all clinically node-negative cases, and complete lymphadenectomy is reserved for patients with confirmed nodal involvement or symptomatic disease. While surgery is essential, it is insufficient alone and must be integrated into a multidisciplinary model involving accurate staging, oncologic follow-up, and immunotherapy in advanced stages. This review highlights the crucial role of the surgeon as an active member of the comprehensive care team to improve survival and quality of life in patients with MCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.